Genix Pharmaceuticals Corporation
GENX.V
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -64.20% | -67.39% | -68.48% | -41.67% | 575.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -64.20% | -67.39% | -68.48% | -41.67% | 575.00% |
| Cost of Revenue | 2,119.67% | 1,920.90% | -80.60% | -79.69% | 916.67% |
| Gross Profit | -7,450.00% | -5,612.50% | -29.17% | 314.29% | 200.00% |
| SG&A Expenses | -30.53% | -37.12% | -14.93% | -36.28% | -28.74% |
| Depreciation & Amortization | -99.74% | -99.80% | -75.47% | -51.67% | -29.22% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.66% | -56.82% | -56.06% | -46.29% | -28.20% |
| Operating Income | 46.38% | 56.68% | 55.89% | 46.35% | 29.26% |
| Income Before Tax | 97.24% | 98.33% | -348.50% | -312.13% | -323.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 97.24% | 98.33% | -348.50% | -312.13% | -323.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 97.24% | 98.33% | -348.50% | -312.13% | -323.20% |
| EBIT | 46.38% | 56.68% | 55.89% | 46.35% | 29.26% |
| EBITDA | 122.62% | 115.25% | 115.76% | 79.10% | 33.40% |
| EPS Basic | 97.15% | 98.35% | -351.82% | -316.39% | -327.64% |
| Normalized Basic EPS | 23.33% | 41.10% | 39.13% | 36.36% | 23.08% |
| EPS Diluted | 97.15% | 98.35% | -351.82% | -316.39% | -327.64% |
| Normalized Diluted EPS | 23.33% | 41.10% | 39.13% | 36.36% | 23.08% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |